The Role of Axillary Lymph Node Dissection in Tubular Carcinoma of the Breast: A Population Database Study

Shuang-Long Chen*  
Wen-Wen Zhang*  
Jun Wang  
Jia-Yuan Sun  
San-Gang Wu  
Zhen-Yu He

* Shuang-Long Chen and Wen-Wen Zhang contributed equally to this work

Source of support: This study was partly supported by the Natural Science Foundation of Guangdong Province (No. 2018A030313666), the Natural Science Foundation of Fujian Province (No. 2016J01635), and the Science and Technology Planning Projects of Xiamen Science and Technology Bureau (No. 350220174070)

Background: The aim of this study was to investigate the role of axillary lymph node dissection on the outcome of patients with tubular carcinoma of the breast.

Material/Methods: Patients diagnosed with tubular carcinoma of the breast between 2000–2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Statistical analysis of the data was undertaken, including analysis of breast cancer-specific survival (BCSS).

Results: Of the 5,645 patients identified on the SEER database with tubular carcinoma of the breast, 5,032 (89.4%) patients had undergone axillary lymph node dissection, with significantly increased rates after 2002 compared with rates between 2000–2001 (p <0.001), which stabilized between 2002–2013 (p=0.330). Axillary lymph node metastases were present in 6.1% of all patients and in 5.3% of patients with a tumor size £2 cm. Lymph node-positive disease was associated with patient age £65 years, intermediate-grade or high-grade tumors, and tumor size >2.0 cm. Axillary lymph node dissection was an independent prognostic indicator. The 10-year BCSS was 97.3% and 96.6% in patients with and without axillary lymph node dissection, respectively (p=0.002). The number of removed lymph nodes was not related to breast cancer-specific survival.

Conclusions: In patients with tubular carcinoma of the breast, lymph node status was not associated with significant breast cancer-specific survival. However, axillary lymph node dissection may still be considered for patients with for tubular carcinoma of the breast even in patients with a small tumor size.

MeSH Keywords: Breast Neoplasms • Lymph Node Excision • Risk Factors • Survival Analysis

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/913077
Background

Tubular carcinoma is a rare subtype of breast cancer that is associated with an excellent prognosis, and most patients are diagnosed with small tumor size with a low incidence of lymph node involvement and recurrence [1–3]. Tubular carcinoma of the breast is characterized histologically by well-differentiated carcinoma cells that form small glandular structures or well-formed tubules that resemble ductules in non-neoplastic breast tissue [4]. The incidence of detection and diagnosis of tubular carcinoma of the breast has increased in the era of breast screening programs, accounting for approximately 1–5% of all breast cancers [1,2,5,6].

Sentinel lymph node biopsy has been confirmed to be an effective method of axillary lymph node staging and is part of the optimal management of patients with low-risk breast cancers, including tubular carcinoma [7]. However, controversy remains regarding the frequency of axillary metastases and the role of examination of the axillary tissues in patients with tubular carcinoma of the breast. Several studies have indicated that axillary lymph node dissection may be unnecessary in patients with tubular carcinoma with a small tumor size [8–10]. However, there remains no consensus on the role of axillary lymph node dissection in patients with tubular carcinoma. Also, although studies on invasive ductal carcinomas have confirmed a significant association between the size of the primary tumor and the probability of lymph node metastasis [11,12], the association between primary tumor size and the risk of lymph node metastasis in tubular carcinoma of the breast remains controversial [1,8,13–15].

Therefore, the aim of this study was to investigate the role of axillary lymph node dissection on the outcome of patients with tubular carcinoma of the breast using a patient population from the from the Surveillance, Epidemiology, and End Results (SEER) database.

Material and Methods

Patient characteristics from the patient database

Patients with tubular carcinoma of the breast who were diagnosed between 2000–2013 from the current Surveillance, Epidemiology, and End Results database (SEER) program were included in the study. The SEER database is maintained by the National Cancer Institute (NCI), which includes de-identified patient information, this study was exempt from evaluation by the institutional review board or the requirement for patient consents.

Statistical analysis

Binary logistic regression was performed to assess the predictive indicators for axillary lymph node dissection. The Kaplan-Meier method estimated breast cancer-specific survival (BCSS) curves and overall survival (OS) rates and compared using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model with the backward version of the Wald parametric statistical method. All statistical tests were performed using SPSS, version 22 (IBM Corporation, Armonk, NY, USA). Tests were two-sided, and a p-value <0.05 was considered to be statistically significant.

Results

Patient characteristics

There were 5,645 patients with tubular breast carcinoma identified from the Surveillance, Epidemiology, and End Results database (SEER) database who met the study inclusion criteria. Figure 1 shows the patient selection flowchart for the study. The median patient age was 65 years, and 85.5% (n=4,829) of the patients were non-Hispanic and Caucasian. Patients with tubular carcinoma of the breast had favorable clinicopathologic characteristic including well-differentiated histology (low grade) (n=5,168, 91.6%), small tumor size ≤2 cm (n=5,411, 95.9%), lymph node negative disease (n=5,300, 93.9%), estrogen receptor (ER)-positive tumor status (n=5,534, 98.0%), progesterone receptor (PR)-positive tumor status (n=4,767, 84.4%), and human epidermal growth factor receptor 2 (HER2)-negative tumor status (n=1050, 98.2%). Also, a total of 4,342 (76.9%) and 3,364 (59.6%) patients received breast-conserving surgery (BCS) and postoperative radiotherapy, respectively. The patient characteristics are shown in Table 1.

The temporal trends of axillary lymph node dissection

A total of 5,032 (89.4%) patients underwent axillary lymph node dissection. The median number of excised lymph nodes was 3 (range, 1–45), and 83.0% (n=4,175) of patients had less than 10 excised lymph nodes. Figure 2 illustrates the temporal trends for axillary lymph node dissection between 2000–2013. Notably, the use of axillary lymph node dissection significantly increased after 2002 (p<0.001) compared with the years between 2000–2001, which was then stable from 2002–2013, with no significant change over time (p=0.330). In patients with
Figure 1. Flowchart of the patient selection used in the study.

Table 1. The baseline characteristics of 5645 patients with tubular carcinomas of the breast.

| Variables                  | n (%)          |
|----------------------------|----------------|
| Age (years)                |                |
| <65                        | 3529 (62.5)    |
| ≥65                        | 2116 (37.5)    |
| Race                       |                |
| Non-Hispanic White         | 4829 (85.5)    |
| Non-Hispanic Black         | 243 (4.3)      |
| Hispanic                   | 315 (5.6)      |
| Other                      | 258 (4.6)      |
| Grade                      |                |
| Well differentiated         | 5168 (91.6)    |
| Moderately differentiated   | 424 (7.5)      |
| Poorly/undifferentiated    | 53 (0.9)       |
| Tumor size (cm)            |                |
| ≤2                         | 5411 (95.9)    |
| >2≤5                       | 204 (3.6)      |
| >5                         | 30 (0.5)       |
| Tumor stage (n=5367)       |                |
| T1a                        | 1413 (26.3)    |
| T1b                        | 2510 (46.8)    |
| T1c                        | 1444 (26.9)    |
| Nodal status               |                |
| Negative                   | 5300 (93.9)    |
| Positive                   | 345 (6.1)      |
| ER – estrogen receptor; HER2 – human epidermal growth receptor 2; PR – progesterone receptor; T – tumor.
node-positive disease, the median number of positive lymph nodes was 1 (range, 1–13). The distribution of the number of positive lymph nodes is shown in Figure 3.

Predictive factors for lymph node metastasis in tubular carcinoma of the breast

Multivariate logistic regression analysis was used to determine the predictive factors independently associated with lymph node-positive disease (Table 2). The results indicated that there was an increasing probability of lymph node metastasis in patients aged ≤65 years, patients with intermediate-grade to high-grade tumors, and tumor size >2 cm. In the entire cohort, 6.1% (n=345) of patients were lymph node-positive, and the distribution of lymph node-positive disease was 82.0% (n=283), 17.4% (n=60), and 0.6% (n=2) of the 345 patients with tumor size ≤2 cm, >2 cm, ≤5 cm, and >5 cm, respectively (p<0.001).

Further subgroup analysis in patients with stage T1a tubular carcinoma (tumor size >0.1 cm and ≤0.5 cm), stage T1b tubular carcinoma (tumor size >0.5 cm and ≤1.0 cm), and stage T1c tubular carcinoma (tumor size >1.0 cm and ≤2.0 cm) (n=5367) was performed (Table 2). The results showed that patients aged ≤65 years, with intermediate-grade to high-grade tumors, and tumor size >0.5 cm, were associated with an increased risk of lymph node metastasis. In this subgroup, 5.3% (n=283) of patients had lymph node-positive disease, and the distribution of lymph node-positive disease was 11.7% (n=33), 38.5% (n=109), and 49.8% (n=141) in the 283 patients with stage T1a, T1b, and T1c tubular carcinoma, respectively (p<0.001).

The effect of axillary lymph node dissection on breast cancer-specific survival (BCSS)

The demographic, clinicopathologic, and treatment variables underwent multivariate analysis to evaluate the effect of axillary lymph node dissection on breast cancer-specific survival (BCSS) (Table 3). The results showed that the absence of axillary lymph node dissection was independently associated with poor BCSS. The 10-year BCSS was 97.3% and 96.6% in patients with and without axillary lymph node dissection, respectively (p=0.002) (Figure 4). Also, older age (≥65 years), non-Caucasian race, a previous mastectomy, and no history of postoperative radiotherapy were also the prognostic factors independently associated with a poor BCSS. Multivariate analysis of patients undergoing axillary lymph node dissection showed that the number of removed lymph nodes was not associated with BCSS (Table 3).

Discussion

Approximately 30% of patients with invasive ductal carcinoma (IDC) have lymph node metastases [12], while only between 6.0–16.0% of patients with tubular carcinoma present with lymph node-positive disease [1,2,5,15], which was similar to the findings in this our population database study. However, it was not possible to obtain data on lymph node morphology from the Surveillance, Epidemiology, and End Results database (SEER) database. However, previous studies have indicated that the rate of lymph node macrometastasis, micrometastasis,
and single-cell metastasis was 26.1–28.6%, 42.9–65.2%, and 8.7–28.6%, respectively, in patients with lymph node-positive disease [17,18]. Although lymph node status was not a prognostic factor for patient survival in tubular carcinoma in this study, patients with lymph node macrometastasis might be more prone to distant tumor dissemination [15]. The current National Comprehensive Cancer Network (NCCN) guidelines for the treatment of tubular carcinoma of the breast includes the evaluation of the patient’s axillary lymph node status, with the requirement that it is necessary to assess the patient’s axillary lymph node status to guide the choice of adjuvant therapy [19].

Previously published studies have shown that in patients with tubular carcinoma of the breast, approximately 11.7–17.4% of patients had no axillary lymph node dissection [14,20]. In the present study, 10.6% of patients were omitted from axillary lymph node dissection, and there was a significant increase in axillary lymph node dissection from 2002 onwards. Three previous randomized clinical trials have been reported that enrolled patients between 1998–2004 to compare the regional tumor control, patient survival and treatment side-effects between the time of sentinel lymph node biopsy and axillary lymph node dissection [21–23]. Therefore, a possible explanation for this trend may be related to the increased use of sentinel lymph node biopsy in early-stage breast cancer. Although the SEER data did not record the details of the axillary lymph node dissection of patients, the data from the present study support the hypothesis that most patients who underwent sentinel lymph node biopsy had a median number of three removed axillary lymph nodes.

Table 2. Multivariable logistic regression analysis for factors predictive of nodal-positive disease.

| Variables                          | Entire cohort | T1 stage |
|-----------------------------------|--------------|----------|
|                                   | OR  | 95% CI  | p    | OR  | 95% CI  | p    |
| Age (years)                       |     |         |      |     |         |      |
| <65                               | 1.00| 1       |      | 1.21| 1.01–1.43| 0.04|
| ≥65                               | 0.737| 0.580–0.936| 0.012| 0.677| 0.520–0.881| 0.004|
| Race                              |     |         |      |     |         |      |
| Non-Hispanic White                | 1.00| 1       |      | 1.00| 1       |      |
| Non-Hispanic Black                | 1.382| 0.858–2.226| 0.183| 1.157| 0.669–2.001| 0.602|
| Hispanic                          | 1.422| 0.936–2.160| 0.099| 1.348| 0.842–2.159| 0.213|
| Other                             | 0.928| 0.544–1.581| 0.782| 1.014| 0.555–1.853| 0.964|
| Grade                             |     |         |      |     |         |      |
| Well differentiated               | 1.00| 1       |      | 1.00| 1       |      |
| Moderately, poorly/undifferentiated | 1.534| 1.098–2.144| 0.012| 1.525| 1.057–2.200| 0.024|
| Tumor size (cm)                   |     |         |      |     |         |      |
| ≤2                                | 1.00| 1       |      | 1.00| 1       |      |
| >2                                | 6.274| 4.571–8.613| <0.001| 2.732| 1.919–3.896| <0.001|
| ER                                |     |         |      |     |         |      |
| Negative                          | 1.00| 1       |      | 1.00| 1       |      |
| Positive                          | 1.256| 0.892–1.768| 0.192| 1.223| 0.846–1.767| 0.285|
| PR                                |     |         |      |     |         |      |
| Negative                          | 1.00| 1       |      | 1.00| 1       |      |
| Positive                          | 1.256| 0.892–1.768| 0.192| 1.223| 0.846–1.767| 0.285|
| Tumor stage                       |     |         |      |     |         |      |
| T1a                               | 1.00| 1       |      | 1.00| 1       |      |
| T1b                               | 1.00| 1       |      | 1.00| 1       |      |
| T1c                               | 1.00| 1       |      | 1.00| 1       |      |

CI – confidence interval; ER – estrogen receptor; OR – odds ratio; PR – progesterone receptor; T – tumor.
| Variables                  | Entire cohort |         |         |         | With axillary intervention |         |         |         |
|---------------------------|---------------|---------|---------|---------|----------------------------|---------|---------|---------|
|                           | **HR** | **95% CI** | **p**  | **HR** | **95% CI** | **p**  | **HR** | **95% CI** | **p**  |
| **Age (years)**           |        |         |         |        |              |         |        |              |         |
| <65                       | 1      | 1       |        | 1      |              |        | 1      |              |        |
| ≥65                       | 2.409  | 1.498–3.874 | <0.001 | 2.597  | 1.539–4.385 | <0.001 |        |              |         |
| **Race**                  |        |         |         |        |              |         |        |              |         |
| Non-Hispanic White        | 1      | 1       |        | 1      |              |        | 1      |              |        |
| Non-Hispanic Black        | 3.572  | 1.761–7.244 | <0.001 | 3.291  | 1.397–7.749 | 0.006  |        |              |         |
| Hispanic                  | 0.951  | 0.298–3.042 | 0.933  | 0.844  | 0.204–3.484 | 0.814  |        |              |         |
| Other                     | 1.323  | 0.478–3.656 | 0.590  | 1.573  | 0.565–4.379 | 0.386  |        |              |         |
| **Grade**                 |        |         |         |        |              |         |        |              |         |
| Well differentiated        | 1      | 1       |        | 1      |              |        | 1      |              |        |
| Moderately, poorly/undifferentiated | 0.745  | 0.318–1.743 | 0.497  | 0.930  | 0.392–2.206 | 0.869  |        |              |         |
| **Tumor size (cm)**       |        |         |         |        |              |         |        |              |         |
| ≤2                        | 1      | 1       |        | 1      |              |        | 1      |              |        |
| >2                        | 1.290  | 0.494–3.369 | 0.603  | 1.421  | 0.536–3.768 | 0.480  |        |              |         |
| **Nodal status**          |        |         |         |        |              |         |        |              |         |
| Negative                  | 1      | 1       |        | 1      |              |        | 1      |              |        |
| Positive                  | 1.475  | 0.672–3.236 | 0.332  | 1.561  | 0.694–3.512 | 0.282  |        |              |         |
| **ER**                    |        |         |         |        |              |         |        |              |         |
| Negative                  | 1      | 1       |        | 1      |              |        | 1      |              |        |
| Positive                  | 0.501  | 0.172–1.458 | 0.205  | 0.806  | 0.186–3.503 | 0.774  |        |              |         |
| **PR**                    |        |         |         |        |              |         |        |              |         |
| Negative                  | 1      | 1       |        | 1      |              |        | 1      |              |        |
| Positive                  | 0.837  | 0.467–1.499 | 0.550  | 0.909  | 0.461–1.794 | 0.783  |        |              |         |
| **Surgical procedures**   |        |         |         |        |              |         |        |              |         |
| BCS                       | 1      | 1       |        | 1      |              |        | 1      |              |        |
| Mastectomy                | 1.866  | 1.031–3.378 | 0.039  | 1.572  | 0.780–3.170 | 0.206  |        |              |         |
| **Radiotherapy**          |        |         |         |        |              |         |        |              |         |
| No                        | 1      | 1       |        | 1      |              |        | 1      |              |        |
| Yes                       | 0.528  | 0.288–0.968 | 0.030  | 0.417  | 0.246–0.706 | 0.001  |        |              |         |
| **Axillary intervention** |        |         |         |        |              |         |        |              |         |
| No                        | 1      | 1       |        | 1      |              |        | 1      |              |        |
| Yes                       | 0.535  | 0.297–0.964 | 0.037  | –      | –             | –      |        |              |         |
| **Number of removed lymph nodes (n)** |        |         |         |        |              |         |        |              |         |
| <10                       | –      | –       | –      | 1      |              |        | 1      |              |        |
| ≥10                       | –      | –       | –      | 0.803  | 0.425–1.517 | 0.500  |        |              |         |

BCS – breast-conserving surgery; CI – confidence interval; ER – estrogen receptor; HR – hazard ratio; PR – progesterone receptor.
The relationship between tumor size and the probability of lymph node metastasis in tubular carcinoma of the breast is controversial. Several previous studies have not supported that tumor size was a determinant of axillary lymph node involvement in tubular carcinoma. However, some studies have shown that tumor size was a determinant of axillary lymph node dissection, lymph node morphological characteristics, and the patterns of disease recurrence were also not documented in the SEER database. However, the primary strength of this study was that it involved a large population-based register to assess the probability of lymph node metastasis between pure and mixed tubular carcinoma. Also, axillary lymph node dissection, lymph node morphological characteristics, and the patterns of disease recurrence were also not documented in the SEER database.

This study had several limitations. First, this study was a retrospective analysis of data from a population database, with possible limitations including data recording, patient selection bias, and inherent bias. Second, the cases identified from the SEER database lacked central pathology review and confirmation of the tumor diagnosis, size, and grade, and there may have been a difference in the presentation of lymph node metastasis between pure and mixed tubular carcinoma. Also, axillary lymph node dissection, lymph node morphological characteristics, and the patterns of disease recurrence were also not documented in the SEER database. However, the primary strength of this study was that it involved a large population-based register to assess the probability of lymph node metastasis, risk factors affecting lymph node metastasis, and treatment outcomes in tubular carcinoma of the breast.
Conclusions

The results of this study showed that tubular carcinoma is a subtype of breast cancer with favorable biological behavior including a lower risk of lymph node metastasis. Although the status of lymph nodes was not associated with breast cancerspecific survival (BCSS), axillary lymph node dissection must be considered for tubular carcinoma of the breast even in patients with a tumor size of less than 1 cm. Also, well-designed and controlled randomized studies with long-term follow-up are required to adequately evaluate the role of axillary lymph node dissection in tubular carcinoma of the breast and patient prognosis.

Conflict of interest

None.

References:

1. Diab SG, Clark GM, Osborne CK et al: Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol, 1999; 17(5): 1442–48
2. Rakha EA, Lee AH, Evans AJ et al: Tubular carcinoma of the breast: Further evidence to support its excellent prognosis. J Clin Oncol, 2010; 28(1): 99–104
3. Livi L, Paier F, Meldolesi E et al: Tubular carcinoma of the breast: Outcome and loco-regional recurrence in 307 patients. Eur J Surg Oncol, 2005; 31(1): 9–12
4. Rosen PP: Tubular carcinoma. In: Rosen’s breast pathology. Philadelphia, PA: Lippincott-Raven, 1996: 325–26
5. Wasif N, McCullough AE, Gray RJ et al: Influence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique? J Surg Oncol, 2012; 105(6): 586–90
6. Yang M, Bao W, Zhang X et al: Short-term and long-term clinical outcomes of uncommon types of invasive breast cancer. Histopathology, 2017; 71(6): 874–86
7. Gill G: SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): A randomized controlled surgical trial. Ann Surg Oncol, 2009; 16(2): 266–75
8. Cabral AH, Recine M, Paramo JC et al: Tubular carcinoma of the breast: An institutional experience and review of the literature. Breast J, 2003; 9(4): 298–301
9. Javid SH, Smith BL, Mayer E et al: Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg, 2009; 197(5): 674–77
10. Kader HA, Jackson J, Mates D et al: Tubular carcinoma of the breast: A population-based study of nodal metastases at presentation and of patterns of relapse. Breast J, 2001; 7(1): 8–13
11. He ZY, Wu SG, Yang Q et al: Breast cancer subtype is associated with axillary lymph node metastasis: A retrospective cohort study. Medicine (Baltimore), 2015; 94(48): e2213
12. Wu SG, He ZY, Ren HY et al: Use of CEA and CA15-3 to predict axillary lymph node metastasis in patients with breast cancer. J Cancer, 2016; 7(1): 37–41
13. Winchester DJ, Sahin AA, Tucker SL et al: Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Ann Surg, 1996; 223(3): 342–47
14. Hansen CJ, Kenny L, Lakhami SR et al: Tubular breast carcinoma: An argument against treatment de-escalation. J Med Imaging Radiat Oncol, 2012; 56(1): 116–22
15. Min Y, Bae SY, Lee HC et al: Tubular carcinoma of the breast: clinicopathologic features and survival outcome compared with ductal carcinoma in situ. J Breast Cancer, 2013; 16(4): 404–9
16. Surveillance, Epidemiology, and End Results (SEER) Program Database. Incidence 18 Nov 2015 (2000–2013). Released July 2016, based on the November 2015 submission. Available at: URL: www.seer.cancer.gov
17. Dejode M, Sagan C, Campion L et al: Pure tubular carcinoma of the breast and sentinel lymph node biopsy: A retrospective multi-institutional study of 234 cases. Eur J Surg Oncol, 2013; 39(3): 248–54
18. Fedko MG, Scow JS, Shah SS et al: Pure tubular carcinoma and axillary nodal metastases. Ann Surg Oncol, 2010; 17(Suppl. 3): 338–42
19. Gradishar WJ, Anderson BO, Balassanian R et al: NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw, 2017; 15(4): 433–51
20. Poirier E, Desbiens C, Poirier B et al: Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast. J Surg Oncol, 2018; 117(6): 1137–43
21. Krag DN, Anderson SJ, Julian TB et al: Sentinel-lymph-node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol, 2010; 11(10): 927–33
22. Canavese G, Catturich A, Vecchio C et al: Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: Results of randomized trial. Ann Oncol, 2009; 20(6): 1001–7
23. Zavagno G, De Salvo GL, Scala G et al: A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: Results of the Sentinelia/GIVOM trial. Ann Surg, 2008; 247(2): 207–13
24. Lea V, Gluch L, Kennedy CW et al: Tubular carcinoma of the breast: Axillary involvement and prognostic factors. ANZ J Surg, 2015; 85(6): 448–51
25. Papadatos G, Rangan AM, Psarianos T et al: Probability of axillary node involvement in patients with tubular carcinoma of the breast. Br J Surg, 2001; 88(6): 860–64
26. Stolnicu S, Moldovan C, Resekova E: Even small pure tubular carcinoma of the breast (stage T1a and T1b) can be associated with lymph node metastases – The U T MD Anderson Cancer Center experience. Eur J Surg Oncol, 2016; 42(6): 911–12